Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Lancet Neurol. 2012 Oct 4;11(11):963–972. doi: 10.1016/S1474-4422(12)70213-2

Table 5.

Comparison of clinico-radiological characteristics between MS patients demonstrating MME and not demonstrating MME during the study

MS Patients that demonstrated MME during the study (n=10) MS patients that did not demonstrate MME during the study (n=151) P-value
Clinico-radiological characteristics
 Baseline Gd-enhancing lesion1 2 (25%) 12 (12%) 0.29
 EDSS progression2,3, n (%) 2 (20%) 41 (28%) 0.59
 New Gd-enhancing lesion4, n (%) 2 (20%) 24 (16%) 0.76
 New T2 lesion4, n (%) 4 (40%) 45 (30%) 0.53
 Non-ocular relapse5, n (%) 3 (43%) 32 (28%) 0.41
 Relapse or New Gd-enhancing lesion5, n (%) 4 (57%) 45 (39%) 0.30
1

Available for 8 MME and 100 non-MME patients

2

EDSS progression defined as a ≥ 1-point increase if EDSS < 6·0 and a ≥ 0·5 point increase if EDSS ≥ 6·0

3

Available for 10 MME patients and 147 non-MME patients

4

Available for 10 MME patients and 148 non-MME patients

5

Only patients with relapsing-remitting multiple sclerosis (7 MME patients and 114 non-MME) were included in these analyses